I have been watching several up-and-coming biotechs very closely, and well, a few stocks may be starting to gain some attention by some smart-money institutions. They are, Proteostasis Therapeutics, Inc. (PTI), who is a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases.
The other is company to watch is Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Viking's lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.
The company, with its vast pipeline, also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.
In addition to its multiple shots at the goal, it also develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Like this isn't enough!
Take a look at these companies as you diversify your holdings in 2018.
Disclosure: I am/we are long VKTX.